Categories: Reuters

U.S. to propose TV ads for drugs must include list prices

(Reuters) – The U.S. government, in an effort to increase pressure on drugmakers to lower costs for U.S. consumers, said on Monday it will propose requiring companies to include the price of their prescription medicines in television ads.

Health and Human Services (HHS) Secretary Alex Azar, in announcing the plan, dismissed suggestions by major U.S. drug companies that less stringent disclosures might be adequate.

Azar said HHS would soon propose the rule that would force companies to include the list prices paid by the government’s Medicare or Medicaid programs in direct-to-consumer commercials. The policy was previously suggested in President Donald Trump’s “blueprint” to lower U.S. drug prices.

“We will not wait for an industry with so many conflicting and perverse incentives to reform itself,” Azar said, speaking at the National Academy of Medicine’s Annual President’s Forum.

The proposed rule would work to inject greater transparency into the prices prescription drug manufacturers set and would give beneficiaries important information they need to make informed decisions based on cost, the U.S. Centers for Medicare & Medicaid Services said in a news release.

Earlier on Monday, the Pharmaceutical Research and Manufacturers of America (PhRMA), the industry’s top U.S. lobbying group, announced that its members would include directions in their commercials for patients to find information about the potential price of medicines, such as company websites.

It did not pledge to include the list price in commercials, arguing that they do not reflect the final amount paid by patients as it excludes rebates and discounts drugmakers may offer. PhRMA said including the list price in commercials could discourage patients from seeking needed medical care.

PhRMA represents major U.S. companies, such as Abbvie Inc <ABBV.N>, Pfizer Inc <PFE.N> and Merck & Co <MRK.N>.

The industry will also launch a new platform that will give patients and providers cost and financial assistance information for branded medicines, the group said.

Under the proposed rule, the price to be posted in legible text at the end of an ad would be for a typical course of treatment for an acute medication, such as an antibiotic, or for a 30-day supply of medication for a chronic condition, like high blood pressure. HHS said it would maintain a public list of drug advertisements that do not comply.

(Reporting by Michael Erman in New York and Manogna Maddipatla in Bengaluru; Editing by Sai Sachin Ravikumar and Bill Berkrot)


Recent Posts

  • Articles

Conference Highlights: Hypertension 2018

New research was presented at Hypertension 2018, the Joint Hypertension 2018 Scientific Sessions of the American Heart Association (AHA) Council…

23 hours ago
  • Articles

Developing a More Accurate Measure of Body Fat

Previous studies indicate that body adiposity is associated with diabetes, myocardial infarction, stroke, hypertension, certain cancers, and mortality. BMI has…

1 day ago
  • He doors quick child

Should Doctors Stay in “Our Own Lane” as Commanded by the NRA?

By Linda Girgis, MD Editor in Chief, Physician's Weekly As doctors, we are driven to find the evidence behind the…

2 days ago
  • Articles

Atopic Dermatitis & Extra-Cutaneous Infections

While previous research has established a link between atopic dermatitis (AD) and cutaneous infections, few studies have examined the relationship…

2 days ago
  • Articles

Injection Drug Networks, Viral Suppression, & HIV Transmission

Study results suggest strong associations between the injection network size of people who use injection drugs and both needle sharing…

3 days ago
  • Articles

Frailty, Disability & Mortality in the ICU

As patients increasingly survive critical illness, evidence is mounting to show that survivorship is fraught with cognitive problems, disability, and…

4 days ago